Icotinib plus chemotherapy before surgery for EGFR lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign an informed consent form.
- You have lung adenocarcinoma confirmed by lab tests within the last 60 days.
- Your cancer has an EGFR mutation of the type Ex19del or L858R (confirmed by a specific test called ARMS).
- Your cancer stage is IIA, IIB, IIIA, or IIIB and it is considered resectable (able to be removed with surgery).
- You can have repeat measurements on imaging (there is at least one measurable spot on CT).
- Your general health is good enough (ECOG 0–1), your blood counts and liver/kidney tests are adequate, and your heart/lung function supports surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests different targeted therapies after surgery to lower the risk of early-stage lung cancer returning. It's designed for patients with high-risk features, and the treatment depends on the genetic changes in the tumor.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.